INTU vs LLY: Which Is the Better Buy?
Side-by-side comparison of Intuit Inc. and Eli Lilly and Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-26.
Intuit Inc. · Technology
$277.13
+25.3% upside to fair value
Med Conviction
Grade B
High Quality
VS
Eli Lilly and Company · Healthcare
$1,183.72
+2.1% upside to fair value
Med Conviction
Grade B
High Quality
QuantHub Verdict
INTU has more upside to fair value
(+25.3%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
INTU |
LLY |
| Current Price |
$277.13 |
$1,183.72 |
| Fair Value Estimate |
$347.25 |
$1,208.00 |
| Upside to Fair Value |
+25.3%
|
+2.1%
|
| Market Cap |
$75.8B |
$1,114.8B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
11.0x
|
26.8x
|
| Price / Sales |
3.5x
|
14.0x
|
| Price / FCF |
8.8x
|
52.7x
|
| Revenue Growth YoY |
+13.7%
|
+47.7%
|
| Gross Margin |
80.9%
|
83.4%
|
| Operating Margin |
28.8%
|
49.7%
|
| Return on Equity |
23.4%
|
92.6%
|
| Dividend Yield |
1.73% |
0.57% |
| FCF Yield |
11.43%
|
1.9%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
Intuit is a financial management software platform serving small and mid-market businesses through QuickBooks, consumers through TurboTax, and consumers through Credit Karma, with a professional tax segment in Lacerte, ProSeries and ProConnect. The business quality is high on fundamentals: TTM gross margin of 80.9%, TTM operating margin of 28.8%, TTM net margin of 21.3%, ROE of 23.4%, and free ca…
Eli Lilly is a global pharmaceutical company whose incretin franchise, led by Mounjaro and Zepbound, has become the dominant growth engine in diabetes and obesity care. The business quality is high: TTM gross margin is 83.4%, TTM operating margin is 49.7%, TTM net margin is 33.5%, and ROE is 92.6%, while revenue grew 47.7% and earnings grew 25.3% in the most recent quarter on a year-over-year bas…
Accumulation Zones
| Metric |
INTU |
LLY |
| Zone Low |
$260.44 |
$906.00 |
| Zone High |
$295.16 |
$1,026.80 |
| In Buy Zone? |
Yes
|
No
|